ライフサイエンスコーパス: orexin A

1 rt, the acute appetite-stimulating effect of orexin A.

2 reboxetine, they were by exogenously applied orexin A.

3 A-A receptor agonist) were injected prior to orexin A.

4 of food-evoked dopamine spikes by intra-VTA orexin-A.

5 the infected hypothalamic neurons contained orexin-A.

6 metabolic activity (CMRglc) than intravenous orexin-A.

7 Orexin A (0, 100, 500, and 1000 pmol, in 0.5 microl arti

8 single intracerebroventricular injection of orexin A (1 and 3 nmol) or orexin B (3 nmol), during the

9 Orexin A (1 micromol/l) caused a 500% increase (P < 0.01

10 Fourth ventricular orexin-A (1 nmol) activated Fos expression in the raphe

11 Nanoinjection of orexin-A (12 pmol) into the rostral raphe pallidus (rRPa

12 rank order of potency orexin A > orexin B > orexin A 16-33, that it bound antagonist ligands with af

13 ng 20 h (4-24 h postinjection period) in the orexin A 3 nmol injected group whilst the frequency of i

14 Central administration of orexin-A acutely suppressed cataplectic behavioral arres

15 ntly dropped during the first hour following orexin A administration, coinciding with orexin A-induce

16 ve behavior and autonomic functions of local orexin-A administration in nonanesthetized rats.

17 Orexin-A administration to the fourth ventricle induced

18 Orexin A altered the intrinsic neuronal properties of GS

19 mic (LH) orexin neurons, increases levels of orexin A and 2-arachidonoylglycerol (2-AG) in the ventra

20 The neuromodulatory peptides orexin A and B are important central nervous system regu

21 The neuropeptides orexin A and B are synthesised by perifornical and later

22 Orexin A and B fibers were visible across the brain, wit

23 Orexin A and B neurons were located in a single populati

24 dentify the specific sites of orexin action, orexin A and B were microinjected into a number of hypot

25 Orexins (hypocretins) are two peptides (orexin A and B) produced from the pre-pro-orexin precurs

26 Orexin A and B, a recently identified pair of neuropepti

27 It is concluded that the peptides orexin A and B, acting on orexin receptors, which are GT

28 e-controlling neuropeptides such as ghrelin, orexin A and neuropeptide Y is also discussed.

29 Orexin A and Orexin B (also known as hypocretins) are ne

30 Orexin A and orexin B stimulate feeding when administere

31 Orexin A and orexin B were microinjected into the perifo

32 de that GSNs are specific target neurons for orexin A and suggest that they may mediate, at least in

33 Orexin-A and -B are brain-gut peptides that stimulate fo

34 It has long been known that orexin-A and -B excite basal forebrain cholinergic neuro

35 These peptides, termed orexin-A and -B, have no significant structural similari

36 the conduits of a negative crosstalk between orexin-A and CRF as demonstrated in transfected cells an

37 le-label immunohistochemistry confirmed that orexin-A and dynorphin-A peptides were highly colocalize

38 pounds including the native agonist peptides orexin-A and orexin-B and the potent therapeutic inhibit

39 Orexin-A and orexin-B are neuropeptides originally ident

40 Melanin concentrating hormone (MCH) and the orexins (A and B) have been identified as neuropeptides

41 s inhibition of the excitatory neuropeptides orexins A and B by design of orexin receptor antagonists

42 xins 1 and 2, and two neuropeptide agonists, orexins A and B, has captured the attention of the scien

43 Hypocretins 1 and 2 (also called orexins A and B, respectively) are hypothalamic neuropep

44 The hypothalamic peptides hypocretin-1 (orexin A) and hypocretin-2 (Hcrt-2; orexin B) are import

45 el, MD led to increased hypothalamic CRH and orexin A, and frontal cortical orexin 1 receptors (OX1R)

46 letely blocked by prior administration of an orexin A antagonist.

47 prepro-orexin mRNA and immunoreactive orexin-A are localized in neurons within and around the

48 Orexin A augmented feeding in the 0-1 h and 1-2 h post-i

49 greatly reduced the binding and function of orexin A but not antagonist ligands.

50 ons, which are inhibited by low glucose, but orexin A caused smaller depolarization than on GSNs and

51 using both calcium mobilization and [(125)I]-orexin-A competition binding.

52 ior or superior colliculi, a large number of orexin-A-containing neuronal processes and terminal arbo

53 pressing excitatory vs. inhibitory inputs to orexin-A-containing neurons in the lateral hypothalamus

54 active neurons were not colocalized with the orexin-A-containing neurons.

55 mplex promotes a long-term disruption of the orexin-A-CRF negative crosstalk.

56 Results showed that orexin-A delivered via the intravenous and nasal routes

57 We find that, as with yohimbine, orexin A depression of excitatory transmission in BNST i

58 While the effects of dynorphin-A and orexin-A desensitize over multiple applications, co-appl

59 The responses both to dynorphin-A and to orexin-A desensitize, but co-application of dynorphin-A

60 Orexin-A elicits arousal EEG during anesthetic burst-sup

61 of the hypothalamus as an area important to orexin A feeding regulation.

62 ucleus possessed little or no immunoreactive orexin A fibres in its core, but had fibres at its perip

63 leaflet contained a plexus of immunoreactive orexin A fibres throughout its rostro-caudal extent.

64 Immunoreactive varicose orexin A fibres were found throughout the hypothalamus.

65 and all were found to contain immunoreactive orexin A fibres.

66 S score (mean+/-SD) at 4 h was higher in the orexin-A group compared to controls (57.3+/-5.8 vs. 40.7

67 frequency was similar in both groups but the orexin-A group demonstrated higher IQ values compared to

68 values remained significantly higher in the orexin-A group for the first 120 min (p=0.008) and subse

69 it was activated with rank order of potency orexin A > orexin B > orexin A 16-33, that it bound anta

70 Orexin A (>/=500 pmol) stimulated feeding in the PFH and

71 Orexin-A had no effect on the resting discharge of affer

72 Concentrations of CSF hypocretin-1 (formerly orexin A) have been measured in many patients with sleep

73 alcohol via stimulation of the hypocretin-1/orexin-A (Hcrt-1/Ox-A) system.

74 Orexin A/hypocretin-1 (oxA/hcrt-1) is known to be a modu

75 of this study show that MTN neurons receive orexin A hypothalamic innervation with a somatotopic arr

76 esencephalic trigeminal nucleus (MTN), using orexin A immunohistochemistry.

77 dbrain-pontine junction part of the nucleus, orexin-A-immunopositive varicosities were relatively mor

78 The presence of orexin A-immunoreactive fibres in the neural architectur

79 tween TRH-immunoreactive nerve terminals and orexin-A-immunoreactive cell bodies.

80 In the caudal pontine MTN, only scattered orexin-A-immunoreactive fibers were found, while more ro

81 lamic orexinergic input, the distribution of orexin A immunoreactivity was examined in the rat mesenc

82 Orexin-A-immunostained nerve fibers and terminals were f

83 cadian system suggests an important role for orexin A in circadian timekeeping processes.

84 s were used to determine the distribution of orexin A in the structures of the hypothalamus and thala

85 evidence for the effectiveness of intranasal orexin-A in alleviating cognitive deficits produced by l

86 Here, we show that NAc microinjection of orexin-A in medial shell amplifies the hedonic impact of

87 The role of orexin-A in recovery of arousal after CA deserves furthe

88 des corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an imp

89 lacked any electrophysiological response to orexin-A in the wake-promoting neurons of the tuberomamm

90 Injection of orexin-A increased vital signs to baseline levels.

91 resistance, and in voltage-clamp recordings orexin-A induced an inward current that reversed near th

92 orexin 1 receptor antagonist (SB334867A) on orexin A-induced feeding and locomotor activity was asse

93 Orexin A-induced feeding was significantly attenuated by

94 A antagonists failed to significantly affect orexin A-induced feeding, but muscimol significantly and

95 significantly and dose dependently inhibited orexin A-induced feeding.

96 ing orexin A administration, coinciding with orexin A-induced feeding.

97 Orexin A-induced locomotor activity was not affected by

98 ent study shows that in vitro application of orexin A induces potentiation of N-methyl-D-aspartate re

99 neurons express OX-R1 and OX-R2 and whether orexin-A inhibits responses to CCK.

100 We examined whether microinjections of orexin-A into the VP hotspot enhance the hedonic impact

101 the treatment group received 0.1 mL of 1 nM orexin-A intraventricularly, while controls received sal

102 Orexin A is a neuropeptide located exclusively in neuron

103 cent studies which suggest that hypocretin 1/orexin A may be involved in modulating arousal states an

104 Together, these data indicate that orexin A may influence food intake by decreasing GABAerg

105 ities within the AccSh, we hypothesized that orexin A may partly regulate feeding behavior and locomo

106 t the hypothesis that the AccSh is a site of orexin A modulation of feeding behavior and locomotor ac

107 here was a strong trend towards an increased orexin-A mRNA expression in the rostral ventrolateral me

108 To test this hypothesis, we measured orexin-A mRNA expression in the rostral ventrolateral me

109 propose that enhanced inhibitory control of orexin-A neurons, and their CB1-mediated disinhibition,

110 Hypocretin (orexin), a neuropeptide synthesized exclusively in the p

111 Orexin A or B (10-1000 nM) directly and reversibly depol

112 Superfusion of orexin A or B (10-300 nM) caused a slow depolarization i

113 he diaphragm, were immunopositive for either orexin-A or MCH.

114 Bath application of orexin-A or orexin-B (30-300 nM) produced a slow depolar

115 the patch solution significantly reduced the orexin A- or B-induced depolarizations.

116 The method was demonstrated by determining orexin A, orexin B, and a novel isoform of rat beta-endo

117 but not the smaller ingestive peptides NPY, orexin A, orexin B, CART (55-102[Met(O)(67)]), MCH, or A

118 behavior had lower hippocampal expression of Orexin A (OrxA).

119 POMC neurons receive orexin-A (OX-A)-expressing inputs and express both OX-A

120 gical signals, with Neuropeptide Y (NPY) and Orexin A (OXA) offering diagnostic information on stress

121 many NPY cells in the grass rat IGL exhibit orexin-A (OXA) fiber appositions.

122 Orexin-A (OXA) increases food intake in rodents, and fas

123 Moreover, administration of the orexin A peptide directly into the ventral tegmental are

124 In dopaminergic neurons of VTA slices, orexin A presynaptically inhibits GABAergic transmission

125 whereas at -70 mV the excitatory response to orexin-A prevails.

126 whereas at -70 mV the excitatory response to orexin-A prevails.

127 tial effects on performance, nasal delivered orexin-A produced a more pronounced reversal of sleep de

128 lications, co-application of dynorphin-A and orexin-A produces a sustained response that reverses dep

129 itize, but co-application of dynorphin-A and orexin-A produces a sustained response.

130 These findings demonstrate that orexin A receptive sites for stimulation of food intake

131 in sleep-deprived animals was accompanied by orexin-A related alterations in local cerebral glucose m

132 s behavioral studies with antagonists at the orexin A-selective receptor, OX(1), have demonstrated it

133 armacological inhibitors, we showed that, in orexin-A-stimulated cells, the AA-derived radioactivity

134 B(1) receptor antagonists on the function of orexin A suggest an interplay between these two systems

135 e highest dose (10 microg/kg) of intravenous orexin-A tested.

136 lly significant interactions between CRF and orexin-A that depend on oligomerization of CRF1 receptor

137 ls to the excitatory effects of both CRF and orexin-A, thus providing a mechanism by which stress ind

138 Addition of orexin A to individual cells expressing an OX(1) sensor

139 Moreover, the ability of orexin A to internalize the CB(1) receptor was also bloc

140 The higher potency of the agonist orexin A to regulate the CB(1)-OX(1) heteromer compared

141 ect of intravenous administration of Hcrt-1 (orexin-A) to anaesthetized rats on glutamate and GABA re

142 In rats resuscitated from CA, orexin-A transiently increased arousal and EEG entropy w

143 The synthesis of orexin A undergoes diurnal variation in certain areas of

144 This effect of orexin A was concentration-dependent and blocked by OX(1

145 Orexin A was found to enhance food intake when injected

146 The response to orexin A was significantly reduced in the presence of th

147 , response of the OX(1) and OX(2) sensors to orexin A was slow, consistent with a multistep binding a

148 Remarkably, orexin A was substantially more potent in producing inte

149 and1 microL of saline with or without 3 nmol orexin-A was infused.

150 he fraction of infected cells that contained orexin-A was lower.

151 The improvement in performance by orexin-A was specific to trials classified as high versu

152 Hypocretin-1 (orexin-A) was administered to sleep-deprived (30-36 h) r

153 Cells immunoreactive for orexin A were noted in the lateral hypothalamic area.

154 but given rAAV-orexin, detectable levels of orexin-A were evident in the CSF, indicating release of

155 Two methods of administration of orexin-A were tested, intravenous injections (2.5-10.0 m

156 Orexin A, which depolarizes thalamocortical neurons loca

157 These were also internalized by the peptide orexin A, which has no direct affinity for the cannabino

158 We hypothesized that orexin-A would improve arousal and EEG entropy after CA.